Last checked at 9 Dec 2015 07:00
9 December 2015
Deltex Medical Group plc
("Deltex Medical" or "the Company")
Two new US platform programme accounts opened: fourth hospital system procurement framework agreement in place
Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), is pleased to announce that it has added two further new accounts to its platform programme in the USA.
The two new hospitals are two of the larger hospitals within a nine hospital system and both completed successful clinical evaluations of the Company's ODM products in the first half of the year.
The hospital system has put in place a procurement agreement that will allow other member hospitals to move more quickly in future from clinical evaluation to implementation. This is the fourth US hospital system to put such an agreement in place.
The hospitals have indicated an initial probe purchase requirement of 40 and 50 probes per month respectively. To help the hospitals achieve use of over 100 probes per month each, the Company is recruiting two new clinical trainers who will support these new accounts together with a small number of further local accounts. The two new accounts become the second and third platform programme accounts in the Company's Mid-Atlantic sales territory established in the final quarter of 2014.
These are the fifth and sixth new platform programme accounts that Deltex has secured since September bringing the total number of US platform accounts to 17, including 11 new ones in the year to date, further illustrating the success of the Company's ongoing strategy to focus on the USA and develop it as its key market.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"The USA continues to be an increasingly important market for us and we see it moving even closer towards becoming our key territory for development as adoption rates continue to outperform our other areas of focus. We look forward to working with the teams at both these new accounts and are pleased to have the tenth and eleventh accounts added to our US platform programme this year and the sixteenth and seventeenth in total. Deltex Medical is now over half way towards our current goal of 30 US hospitals on our platform programme by mid-2016."
For further information, please contact:-
Deltex Medical Group plc | 01243 774 837 investorinfo@deltexmedical.com |
Nigel Keen, Chairman |
|
Ewan Phillips, Chief Executive |
|
Jonathan Shaw, Finance Director Barry Curtis, Company Secretary |
|
|
|
Nominated Adviser & Broker |
|
Arden Partners plc | 020 7614 5900 |
Chris Hardie |
|
Joint Broker Zeus Capital Limited Phil Walker Dominic Wilson
|
020 3829 5000
|
Financial Public Relations |
|
IFC Advisory | 0203 053 8671 |
Tim Metcalfe Graham Herring Heather Armstrong |
|
|
|
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.
During 2013, the Company launched the CardioQ-ODM+ monitor that offers clinicians both of the two best-established technologies, Deltex Medical's ODM technology as well as Pulse Pressure Waveform Analysis ('PPWA') in one monitor. This allows clinicians to have unique real time insights into each of flow, pressure and resistance, the three pillars of haemodynamics.
Company goal
ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.
The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.
There are over 3,200 monitors installed in hospitals around the world and over 600,000 patients have been treated to date using Deltex Medical's single patient disposable probes.